196 related articles for article (PubMed ID: 33789001)
21. Regulatory news: Dojolvi (triheptanoin) as a source of calories and fatty acids in long-chain fatty acid oxidation disorders: FDA approval summary.
Zand D; Doan J; Yi S; Wang J; Ma L; Akinshola E; Chakder S; Meyer J; Pacanowski M; Johnson LL; Donohue K; Beitz J
J Inherit Metab Dis; 2021 May; 44(3):515-517. PubMed ID: 33729583
[No Abstract] [Full Text] [Related]
22. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile.
Gu L; Zhang GF; Kombu RS; Allen F; Kutz G; Brewer WU; Roe CR; Brunengraber H
Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E362-71. PubMed ID: 19903863
[TBL] [Abstract][Full Text] [Related]
23. Triheptanoin: First Approval.
Shirley M
Drugs; 2020 Oct; 80(15):1595-1600. PubMed ID: 32897506
[TBL] [Abstract][Full Text] [Related]
24. Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
Tucci S; Floegel U; Beermann F; Behringer S; Spiekerkoetter U
J Lipid Res; 2017 Jan; 58(1):196-207. PubMed ID: 27884962
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases.
Wehbe Z; Tucci S
J Inherit Metab Dis; 2020 May; 43(3):385-391. PubMed ID: 31778232
[TBL] [Abstract][Full Text] [Related]
26. Heptanoate is neuroprotective in vitro but triheptanoin post-treatment did not protect against middle cerebral artery occlusion in rats.
Tan KN; Hood R; Warren K; Pepperall D; Carrasco-Pozo C; Manzanero S; Borges K; Spratt NJ
Neurosci Lett; 2018 Sep; 683():207-214. PubMed ID: 30076987
[TBL] [Abstract][Full Text] [Related]
27. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.
Roe CR; Brunengraber H
Mol Genet Metab; 2015 Dec; 116(4):260-8. PubMed ID: 26547562
[TBL] [Abstract][Full Text] [Related]
28. Resting and total energy expenditure of patients with long-chain fatty acid oxidation disorders (LC-FAODs).
DeLany JP; Horgan A; Gregor A; Vockley J; Harding CO; Gillingham MB
Mol Genet Metab; 2023 Mar; 138(3):107519. PubMed ID: 36696737
[TBL] [Abstract][Full Text] [Related]
29. Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
Borges K; Sonnewald U
Epilepsy Res; 2012 Jul; 100(3):239-44. PubMed ID: 21855298
[TBL] [Abstract][Full Text] [Related]
30. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Bowden A; Chen W; Chen CY; Cataldo J; Marsden D; Kakkis E
J Inherit Metab Dis; 2019 Jan; 42(1):169-177. PubMed ID: 30740733
[TBL] [Abstract][Full Text] [Related]
31. Successful management of rhabdomyolysis with triheptanoin in a child with severe long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency.
Kahraman AB; Yildiz Y; Gokmen-Ozel H; Kadayifcilar S; Sivri S
Neuromuscul Disord; 2023 Apr; 33(4):315-318. PubMed ID: 36893607
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and Clinical Management of Long-chain Fatty-acid Oxidation Disorders: A Review.
Baker JJ; Burton BK
touchREV Endocrinol; 2021 Nov; 17(2):108-111. PubMed ID: 35118456
[TBL] [Abstract][Full Text] [Related]
33. Heat stress deteriorates mitochondrial beta-oxidation of long-chain fatty acids in cultured fibroblasts with fatty acid beta-oxidation disorders.
Li H; Fukuda S; Hasegawa Y; Purevsuren J; Kobayashi H; Mushimoto Y; Yamaguchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1669-72. PubMed ID: 20207594
[TBL] [Abstract][Full Text] [Related]
34. Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver.
Deng S; Zhang GF; Kasumov T; Roe CR; Brunengraber H
J Biol Chem; 2009 Oct; 284(41):27799-27807. PubMed ID: 19666922
[TBL] [Abstract][Full Text] [Related]
35. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.
Roe CR; Sweetman L; Roe DS; David F; Brunengraber H
J Clin Invest; 2002 Jul; 110(2):259-69. PubMed ID: 12122118
[TBL] [Abstract][Full Text] [Related]
36. Odd- and even-numbered medium-chained fatty acids protect against glutathione depletion in very long-chain acyl-CoA dehydrogenase deficiency.
Lund M; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Feb; 1868(2):159248. PubMed ID: 36356723
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes in a series of 18 patients with long chain fatty acids oxidation disorders treated with triheptanoin for a median duration of 22 months.
Guffon N; Mochel F; Schiff M; De Lonlay P; Douillard C; Vianey-Saban C
Mol Genet Metab; 2021 Apr; 132(4):227-233. PubMed ID: 33610471
[TBL] [Abstract][Full Text] [Related]
38. Long-chain fatty acid oxidation disorders: managed care and specialty pharmacy implications.
Pannier A
Am J Manag Care; 2020 Aug; 26(7 Suppl):S155-S161. PubMed ID: 32840328
[TBL] [Abstract][Full Text] [Related]
39. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
40. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin.
Schwarzkopf TM; Koch K; Klein J
Neuroscience; 2015 Aug; 300():201-9. PubMed ID: 25982559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
